Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VALOR pediatric heart failure study of vericiguat
NL-OMON60977Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in heart failure (HF) and left ventricular systolic dysfunction (LVSD) comparing Vericiguat with Placebo (2 arms). Primary endpoints: Change from baseline to Week 16 in log-transformed NT-proBNP, Percentage of participants with one or more adverse events and 1 more. Started Jun 2023; status: recruiting.
02
Drugs
vericiguat
03
Conditions
heart failure (HF)left ventricular systolic dysfunction (LVSD)
Beyond the preview
Go deeper on NL-OMON60977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60977.